

Nigel Jepson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12152888/publications.pdf>

Version: 2024-02-01

28
papers

366
citations

1040056

9
h-index

794594

19
g-index

29
all docs

29
docs citations

29
times ranked

666
citing authors

#	ARTICLE	IF	CITATIONS
1	Percutaneous Thrombin Injection: An Alternative Therapy for Iatrogenic Carotid Artery Pseudoaneurysms. <i>EJVES Vascular Forum</i> , 2022, 55, 52-55.	0.4	1
2	3D Printing for Cardiovascular Applications: From End-to-End Processes to Emerging Developments. <i>Annals of Biomedical Engineering</i> , 2021, 49, 1598-1618.	2.5	15
3	A multi-objective optimization of stent geometries. <i>Journal of Biomechanics</i> , 2021, 125, 110575.	2.1	8
4	Cardiac Complications in Patients Hospitalised With COVID-19 in Australia. <i>Heart Lung and Circulation</i> , 2021, 30, 1834-1840.	0.4	10
5	Topological Optimization of Auxetic Coronary Stents Considering Hemodynamics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 728914.	4.1	12
6	Association of hypertension with mortality in patients hospitalised with COVID-19. <i>Open Heart</i> , 2021, 8, e001853.	2.3	4
7	Performance and Safety of Transfemoral TAVI With SAPIEN XT in Australian Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: SOLACEâ€“AUâ€“Trial. <i>Heart Lung and Circulation</i> , 2020, 29, 1839-1846.	0.4	3
8	Letter to the Editor: CSANZ Consensus Guidelines for Interventional Cardiology Services Delivery During COVID-19 Pandemic in Australia and New Zealand. <i>Heart Lung and Circulation</i> , 2020, 29, 1260-1261.	0.4	3
9	Asia Pacific consensus document on coronary bifurcation interventions. <i>EuroIntervention</i> , 2020, 16, e706-e714.	3.2	8
10	South Pacific Underwater Medicine Society guidelines for cardiovascular risk assessment of divers. <i>Diving and Hyperbaric Medicine</i> , 2020, 50, 273-277.	0.5	3
11	Rotational Atherectomy Combined with Drug Coated-Balloons for in-Stent Restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 559-562.	0.8	5
12	Threeâ€“year clinical outcomes of patients treated with everolimusâ€“eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E1-E7.	1.7	11
13	Balloon Aortic Valvuloplasty in the Transcatheter Valve Era: Single Centre Indications and Early Safety Data in a High Risk Population. <i>Heart Lung and Circulation</i> , 2018, 27, 595-600.	0.4	8
14	Coronary stent technology: a narrative review. <i>Medical Journal of Australia</i> , 2017, 206, 413-414.	1.7	0
15	Bioresorbable scaffoldâ€“the holy grail of percutaneous coronary intervention: fact or myth?. <i>Journal of Thoracic Disease</i> , 2016, 8, E589-E592.	1.4	0
16	Coronary stent technology: a narrative review. <i>Medical Journal of Australia</i> , 2016, 205, 277-281.	1.7	16
17	Drug-eluting Balloon Versus Second Generation Drug Eluting Stents in the Treatment of In-stent Restenosis: A Systematic Review and Meta-analysis. <i>Heart Lung and Circulation</i> , 2016, 25, 1184-1194.	0.4	17
18	â€“Full bioresorbable jacketâ€“: Alternative to very long segment metallic stenting in a young patient with diffuse coronary artery disease. <i>International Journal of Cardiology</i> , 2016, 223, 361-363.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Phaeochromocytoma presenting with labile blood pressures following coronary artery bypass grafting. <i>Journal of Cardiac Surgery</i> , 2016, 31, 721-724.	0.7	0
20	Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 169-175.	2.6	6
21	One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. <i>EuroIntervention</i> , 2016, 12, 1255-1262.	3.2	7
22	Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers. <i>Journal of Invasive Cardiology</i> , 2016, 28, 316-22.	0.4	8
23	Periprocedural myocardial infarction is associated with increased mortality in patients with coronary artery bifurcation lesions after implantation of a drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 696-705.	1.7	14
24	Prognostic Significance of Peri-procedural Myocardial Infarction in the Era of High Sensitivity Troponin: A Validation of the Joint ACCF/AHA/ESC/WHF Universal Definition of Type 4a Myocardial Infarction with High Sensitivity Troponin T. <i>Heart Lung and Circulation</i> , 2015, 24, 673-681.	0.4	21
25	Optimal duration of dual antiplatelet therapy following drug-eluting stents implantation: A meta-analysis of 7 randomised controlled trials. <i>International Journal of Cardiology</i> , 2015, 201, 578-580.	1.7	8
26	Peri-procedural myocardial infarction following percutaneous coronary intervention as defined by the Universal Definition predicts increased mortality at 2years. <i>International Journal of Cardiology</i> , 2015, 199, 96-98.	1.7	3
27	Patent Foramen Ovale Influences the Presentation of Decompression Illness in SCUBA Divers. <i>Heart Lung and Circulation</i> , 2015, 24, 26-31.	0.4	19
28	Impact of the Complexity of Bifurcation Lesions Treated With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1266-1276.	2.9	153